Combination Therapy of HAIC and HLX10 and HLX04 in HCC With Major Portal Vein Tumor Thrombosis
Status:
Not yet recruiting
Trial end date:
2024-07-01
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blinded, controlled, phase II study. The purpose is to evaluate
efficacy and safety of the combination therapy of HAIC (Hepatic arterial infusion
chemotherapy) with HLX10 (PD-1 antibody) and HLX04 (VEGF antibody) compared with HAIC and
placebo in patients with hepatocellular carcinoma with major portal vein tumor thrombosis.